

Schwann cell necroptosis in diabetic neuropathy

Alexia Belavgeni^{a,b}, Francesca Maremonti^{a,b}, Marlena Stadtmüller^c, Stefan R. Bornstein^{a,c,d,e,f,g}, and Andreas Linkermann^{a,b,1}

Diabetic neuropathy (DN) is clinically characterized by a “stocking and glove” pattern of symptoms such as sensory loss, numbness, pain, and burning sensations. This pattern implicates that Schwann cells, required to maintain the myelin sheath and the nodes of Ranvier, rather than the neurons themselves, represent the primary site of injury (Fig. 1). In PNAS, Guo et al. (1) explain how the necroptosis protein, mixed-lineage kinase domain-like protein (MLKL), causes Schwann cells to lose their function.

DN is not a classical form of demyelinating neuropathy, such as Guillain-Barré syndrome. However, chronic hyperglycemia in type 1 and type 2 diabetes mellitus patients may induce typical features of demyelination, especially in severely affected patients (2–4). Therefore, understanding the death of Schwann cells might help unravel their mechanistic role in the associated loss of the myelin sheath and clinical progression of DN.

Necroptosis is a form of regulated necrosis that is associated with phosphorylation of MLKL (5, 6), a pseudokinase (7, 8). Although activation of MLKL is not sufficient to kill a cell (9), it is required for necroptosis. The only known kinase to phosphorylate MLKL is receptor-interacting protein kinase 3 (RIPK3) (5, 6) which is controlled by death receptors through RIPK1 (10–13), Toll-like receptors through the protein TIR domain-containing adapter inducing interferon-beta (TRIF) (14–16), and nucleotide sensors such as Z-DNA-binding protein 1 (ZBP1) (13, 17–23). Interaction with these proteins requires the RIP homotypic interacting motif of RIPK3 (24, 25) which is also interfered with by viruses such as cytomegalovirus (25–27), mechanistically highlighting the well-established role for necroptosis in viral defense.

In their current work, Guo et al. (1) first establish a transmission electron microscopy-based readout system of myelin decompaction following streptozotocin (STZ)-induced loss of pancreatic beta cells, thereby inducing diabetes. They demonstrate colocalization of MLKL with a known myelin sheath marker, indicating localization in the Schwann cells. Next, the authors investigate MLKL-deficient mice which exhibit less myelin decompaction and higher nerve conduction velocity in the STZ model, indicating MLKL to mechanistically induce DN. Further, they generate Schwann cell-specific MLKL-deficient mice employing a tamoxifen-inducible Plp1 promoter and confirm the above-mentioned findings. In yet another independent approach, they replace the MLKL gene with an S441A point mutation of MLKL in mice and, once again, reverse the diabetic phenotype in this setting when compared to MLKL wild-type mice. Finally, and clinically most importantly, an MLKL inhibitor (TC013249) is tested. As this inhibitor was generated to ultimately treat humans, human MLKL knock-in mice (hMLKL-KI) are employed for this important set




Fig. 1. Demyelination during DN involves MLKL-mediated damage of Schwann cells. In healthy individuals, the speed at which an electrochemical impulse propagates down a neural pathway, referred to as nerve conduction velocity, requires Schwann cells for electric neuronal isolation. In DN, demyelination of Schwann cells was recognized decades ago and is well known to clinically associate with the stocking-and-glove pattern frequently observed in diabetic patients. Currently, no treatment for DN is clinically available. Guo et al. (1) set out to investigate how Schwann cells lose their function. They report a critical pathophysiological contribution of MLKL, a pseudokinase and key mediator of necroptosis. In the STZ-induced murine model of diabetes and in patients suffering from DN, Schwann cell degradation is a common feature. In that model, MLKL-deficient or MLKL-mutant mice, and wild-type mice treated with the MLKL inhibitor TC013249, exhibited less demyelination.

of experiments. The authors carefully confirm that the hMLKL-KI mice do not express traces of mouse MLKL and control for equal hMLKL expression levels compared to wild-type mice. Intraperitoneal osmotic pumps are used to continuously deliver TC013249 to the hMLKL-KI mice. Upon treatment, significantly mitigated myelin sheath decompaction is observed. This functionally correlates with significantly less STZ-induced decreases in nerve conduction velocity.

MLKL inhibition, however, should be interpreted within a bigger picture. Within the field of neurology, other conditions

Author affiliations: ^aDivision of Nephrology, Department of Internal Medicine 3, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01069 Dresden, Germany; ^bBiotechnology Center, Technische Universität Dresden, 01307 Dresden, Germany; ^cInstitute of Medical Microbiology and Virology, Technische Universität Dresden, 01307 Dresden, Germany; ^dDiabetes and Nutritional Sciences, King's College London, London SE1 1UL, United Kingdom; ^eCenter for Regenerative Therapies, Technische Universität Dresden, 01307 Dresden, Germany; ^fPaul Langerhans Institute Dresden of Helmholtz Centre Munich at University Clinic Carl Gustav Carus of TU Dresden Faculty of Medicine, Technische Universität Dresden, 01069 Dresden, Germany; and ^gLee Kong Chian School of Medicine, Nanyang Technological University, 636921 Singapore

Author contributions: A.B., S.R.B., and A.L. designed research; A.B., F.M., M.S., S.R.B., and A.L. analyzed data; and A.B., F.M., M.S., and A.L. wrote the paper.

The authors declare no competing interest.

Copyright © 2022 the Author(s). Published by PNAS. This article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

See companion article, “Blockage of MLKL prevents myelin damage in experimental diabetic neuropathy,” [10.1073/pnas.2121552119](https://doi.org/10.1073/pnas.2121552119).

¹To whom correspondence may be addressed. Email: andreas.linkermann@ukdd.de.

Published April 21, 2022.

that include demyelination include multiple sclerosis, Marchiafava Bignami disease, central pontine myelinolysis, and others. It will be interesting to investigate the role of MLKL in these disorders. In addition, RIPK1 was demonstrated to play critical roles in diverse pathologies of the central nervous system (28). Interestingly, and somehow in contrast to a proactive role, MLKL-deficient patients may present with features of neurodegeneration (29). Beyond the field of neurology, MLKL was reported to be involved in acute conditions such as ischemia-reperfusion injury (9, 28, 30–34). In the preclinical limelight of the growing body of evidence for MLKL as a mediator of diseases, clinical trials employing MLKL inhibitors will be considered. Naturally, however, inhibiting the downstream target of necroptosis will result in the functional loss of necroptosis upon MLKL inhibition. Although most primary data indicate a viral inhibition of the kinase RIPK3 (11, 27, 35–37) rather than MLKL directly, it must be predicted that viral infections, known to be cleared by necroptosis (38), may appear more frequently. Clinical trials for testing MLKL inhibitors should therefore be designed to include more-detailed

assessments than usual of safety from viral infections and associated complications.

In PNAS, Guo et al. explain how the necroptosis protein, mixed lineage kinase domain-like protein (MLKL), causes Schwann cells to lose their function.

It is estimated that the annual cost of DN is higher than US\$10 billion in the United States (39). In type 2 diabetes mellitus, improvement of glycemic control is thought to have little effect on neuropathy outcomes (39). Opioids are not recommended even in painful DN, owing to the potential for abuse. Novel treatment strategies, therefore, are of paramount clinical importance. In conclusion, the data presented by Guo et al. (1) indicate a therapeutic target in a rodent model that may be of potential future interest and clearly warrants further preclinical and clinical investigations.

ACKNOWLEDGMENTS. Work in the Linkermann Lab is funded by German Research Foundation grants SFB-TRR 205 and SFB-TRR 127, the International Research Training Group 2251, Priority Programme 2306, the Else Kröner-Fresenius Stiftung, and the Wilhelm Sander-Stiftung. A.L. is supported by the German Research Foundation (Heisenberg-Professorship, Project 324141047).

1. J. Guo *et al.*, Blockage of MLKL prevents myelin damage in experimental diabetic neuropathy. *Proc. Natl. Acad. Sci. U.S.A.* **119**, 10.1073/pnas.2121552119 (2022).
2. S. K. Dunnigan *et al.*, Conduction slowing in diabetic sensorimotor polyneuropathy. *Diabetes Care* **36**, 3684–3690 (2013).
3. L. F. Gumy, E. T. Bampton, A. M. Tolkovsky, Hyperglycaemia inhibits Schwann cell proliferation and migration and restricts regeneration of axons and Schwann cells from adult murine DRG. *Mol. Cell. Neurosci.* **37**, 298–311 (2008).
4. A. P. Mizisin, G. D. Shelton, S. Wagner, C. Rusbridge, H. C. Powell, Myelin splitting, Schwann cell injury and demyelination in feline diabetic neuropathy. *Acta Neuropathol.* **95**, 171–174 (1998).
5. L. Sun *et al.*, Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. *Cell* **148**, 213–227 (2012).
6. J. Zhao *et al.*, Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 5322–5327 (2012).
7. J. M. Murphy *et al.*, The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. *Immunity* **39**, 443–453 (2013).
8. J. M. Murphy *et al.*, Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL. *Biochem. J.* **457**, 369–377 (2014).
9. A. von Mässenhausen *et al.*, Phenytoin inhibits necroptosis. *Cell Death Dis.* **9**, 359 (2018).
10. K. Newton, X. Sun, V. M. Dixit, Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. *Mol. Cell. Biol.* **24**, 1464–1469 (2004).
11. Y. S. Cho *et al.*, Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. *Cell* **137**, 1112–1123 (2009).
12. S. He *et al.*, Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. *Cell* **137**, 1100–1111 (2009).
13. M. Rebsamen *et al.*, DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. *EMBO Rep.* **10**, 916–922 (2009).
14. W. J. Kaiser, M. K. Offermann, Apoptosis induced by the Toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. *J. Immunol.* **174**, 4942–4952 (2005).
15. S. He, Y. Liang, F. Shao, X. Wang, Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 20054–20059 (2011).
16. W. J. Kaiser *et al.*, Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. *J. Biol. Chem.* **288**, 31268–31279 (2013).
17. A. Takaoka *et al.*, DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. *Nature* **448**, 501–505 (2007).
18. T. Kuriakose *et al.*, ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. *Sci. Immunol.* **1**, aag2045 (2016).
19. J. Maelfait *et al.*, Sensing of viral and endogenous RNA by ZBP1/DAI induces necroptosis. *EMBO J.* **36**, 2529–2543 (2017).
20. J. P. Ingram *et al.*, ZBP1/DAI drives RIPK3-mediated cell death induced by IFNs in the absence of RIPK1. *J. Immunol.* **203**, 1348–1355 (2019).
21. D. Yang *et al.*, ZBP1 mediates interferon-induced necroptosis. *Cell. Mol. Immunol.* **17**, 356–368 (2020).
22. H. Jiao *et al.*, Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation. *Nature* **580**, 391–395 (2020).
23. T. Zhang *et al.*, Influenza virus Z-RNAs induce ZBP1-mediated necroptosis. *Cell* **180**, 1115–1129.e13 (2020).
24. X. Sun, J. Yin, M. A. Starovasnik, W. J. Fairbrother, V. M. Dixit, Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. *J. Biol. Chem.* **277**, 9505–9511 (2002).
25. W. J. Kaiser, J. W. Upton, E. S. Mocarski, Receptor-interacting protein homotypic interaction motif-dependent control of NF-kappa B activation via the DNA-dependent activator of IFN regulatory factors. *J. Immunol.* **181**, 6427–6434 (2008).
26. J. W. Upton, W. J. Kaiser, E. S. Mocarski, Cytomegalovirus M45 cell death suppression requires receptor-interacting protein (RIP) homotypic interaction motif (RHIM)-dependent interaction with RIP1. *J. Biol. Chem.* **283**, 16966–16970 (2008).
27. J. W. Upton, W. J. Kaiser, E. S. Mocarski, Virus inhibition of RIP3-dependent necrosis. *Cell Host Microbe* **7**, 302–313 (2010).
28. A. Degterev, D. Ofengeim, J. Yuan, Targeting RIPK1 for the treatment of human diseases. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 9714–9722 (2019).
29. S. L. Faergeman *et al.*, A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. *Cell Death Dis.* **11**, 303 (2020).
30. W. Liu *et al.*, RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. *Proc. Natl. Acad. Sci. U.S.A.* **115**, E1475–E1484 (2018).
31. S. Martens *et al.*, Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. *Cell Death Dis.* **8**, e2904 (2017).
32. K. Newton *et al.*, RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. *Cell Death Differ.* **23**, 1565–1576 (2016).
33. H. M. Ni *et al.*, Receptor-interacting serine/threonine-protein kinase 3 (RIPK3)-mixed lineage kinase domain-like protein (MLKL)-mediated necroptosis contributes to ischemia-reperfusion injury of steatotic livers. *Am. J. Pathol.* **189**, 1363–1374 (2019).
34. W. Tonnus *et al.*, Rubicon-deficiency sensitizes mice to mixed lineage kinase domain-like (MLKL)-mediated kidney ischemia-reperfusion injury. *Cell Death Dis.* **13**, 236 (2022).
35. L. P. Daley-Bauer *et al.*, Mouse cytomegalovirus M36 and M45 death suppressors cooperate to prevent inflammation resulting from antiviral programmed cell death pathways. *Proc. Natl. Acad. Sci. U.S.A.* **114**, E2786–E2795 (2017).
36. S. Omoto *et al.*, Suppression of RIP3-dependent necroptosis by human cytomegalovirus. *J. Biol. Chem.* **290**, 11635–11648 (2015).
37. J. W. Upton, W. J. Kaiser, E. S. Mocarski, DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. *Cell Host Microbe* **11**, 290–297 (2012).
38. E. S. Mocarski, J. W. Upton, W. J. Kaiser, Viral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathways. *Nat. Rev. Immunol.* **12**, 79–88 (2011).
39. E. L. Feldman *et al.*, Diabetic neuropathy. *Nat. Rev. Dis. Primers* **5**, 41 (2019).